Decapeptide angiotensin analogues can function as ACE inhibitors and generate octapeptide antagonists in vivo, effectively lowering blood pressure in hypertensive rat models.
Answers are grounded in this paper and cite their sources.
Preclinical rat data should not change practice; leaves open translation of angiotensin analogues to human hypertension therapy.
The octapeptide analogues 8-Cys-AII, 8-Ile-AII, 4-Phe-8-Tyr-AII, and p -fluoro-4-Phe-AII were potent competitive antagonists of angiotensin I and II (AI and AII) in rat uterus strips, whereas the decapeptide analogues 4-Phe-8-Tyr-AI and 8-Ile-AI were weak antagonists, 8-Cys-AII and 8-Ile-AII were potent antagonists of the rise in blood pressure induced by angiotensin, although 4-Phe-8-Tyr-AII and p -fluoro-4-Phe-AII were less potent antagonists. AI was rapidly converted and was equipotent to AII in vivo, but 8-Ile-AI was a hundred times less potent than 8-Ile-AII. However, some conversion of 8-Ile-AI did occur, since SQ 20881 (an inhibitor of angiotensin-converting enzyme) markedly diminished the All antagonistic action of 8-Ile-AI. The decapeptides AI, 8-Ile-AI, and 4-Phe-8-Tyr-AI were potent competitive antagonists of the hydrolysis of hippurylhistidylleucine by converting enzyme in vitro. Infusion of the octapeptide and the decapeptide angiotensin analogues resulted in a significant lowering of the blood pressure in anesthetized rats treated with phenoxybenzamine and propranolol and made acutely hypertensive by unclamping a renal pedicle that had been temporarily occluded. The decapeptide analogues, therefore, can function as inhibitors of angiotensin-converting enzyme and simultaneously generate octapeptide antagonists in vivo.
No takes yet. Share an insight, caveat, or question.
Needleman et al. (1972) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: